Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

      © 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

 Entacapone Chemical-data

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Entacapone Manufacturers in India Suppliers Entacapone Exporters Distributors Entacapone api active pharmaceuticals ingredients Entacapone manufacturers Side Effects bulk drugs raw material Entacapone companies Side Effects Importers Entacapone Entacapone Exporters Entacapone exporters FDA Entacapone DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Entacapone manufacturing pharmaceutical drugs pharmaceutical intermediates Entacapone pharmaceutical chemicals pharmaceutical raw materials Entacapone active pharmaceutical ingredients Entacapone committee active pharmaceutical ingredients manufacturer Entacapone Active Pharmaceutical Ingredients manufacturer Entacapone exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Entacapone, Entacapone manufacturer India, Entacapone product, Entacapone products, Api preparation, Certificate of Analysis API manufacturer product, Entacapone anti ulcer product, Certificate of Origin COA Entacapone COS Entacapone, pharmaceutical generic, pharmaceutical drug, medical, Entacapone pharma healthcare, pharma patents, contract MSDS manufacturing Trader Entacapone pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Entacapone expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Entacapone DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Entacapone ingredients, api, HIV Entacapone, tablets, capsules, syrup & protein Entacapone powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Entacapone gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Entacapone WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

Entacapone chemical_img






HOME >> API >> API List1 >> Entacapone >> Precautions

Molecular Formula C14H15N3O5

Entacapone CAS Number 130929-57-6

Tell your doctor your medical history, including: liver disease, any allergies. To minimize dizziness and lightheadedness, get up slowly when rising from a seated or lying position. This drug may make you dizzy or drowsy; use caution engaging in activities requiring alertness such as driving or using machinery. Limit alcoholic beverages. Entacapone is not indicated for use in children. This medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor. It is not known whether this drug passes into breast milk. Consult your doctor before breast-feeding.

Dopaminergic therapy in Parkinson's Disease patients has been associated with orthostatic hypotension. Entacapone enhances levodopa bioavailability and, therefore, might be expected to increase the occurrence of orthostatic hypotension. In Comtan (entacapone) clinical trials, however, no differences from placebo were seen for measured orthostasis or symptoms of orthostasis. Orthostatic hypotension was documented at least once in 2.7% and 3.0% of the patients treated with 200 mg Comtan and placebo, respectively. A total of 4.3% and 4.0% of the patients treated with 200 mg Comtan and placebo, respectively, reported orthostatic symptoms at some time during their treatment and also had at least one episode of orthostatic hypotension documented (however, the episode of orthostatic symptoms itself was not accompanied by vital sign measurements). Neither baseline treatment with dopamine agonists or selegiline, nor the presence of orthostasis at baseline, increased the risk of orthostatic hypotension in patients treated with Comtan compared to patients on placebo.

In the large controlled trials, approximately 1.2% and 0.8% of 200 mg entacapone and placebo patients, respectively, reported at least one episode of syncope. Reports of syncope were generally more frequent in patients in both treatment groups who had an episode of documented hypotension (although the episodes of syncope, obtained by history, were themselves not documented with vital sign measurement).

In clinical trials, diarrhea developed in 60 of 603 (10.0%) and 16 of 400 (4.0%) of patients treated with 200 mg Comtan and placebo, respectively. In patients treated with Comtan, diarrhea was generally mild to moderate in severity (8.6%) but was regarded as severe in 1.3%. Diarrhea resulted in withdrawal in 10 of 603 (1.7%) patients, 7 (1.2%) with mild and moderate diarrhea and 3 (0.5%) with severe diarrhea. Diarrhea generally resolved after discontinuation of Comtan. Two patients with diarrhea were hospitalized. Typically, diarrhea presents within 4 - 12 weeks after entacapone is started, but it may appear as early as the first week and as late as many months after the initiation of treatment.

Dopaminergic therapy in Parkinson's Disease patients has been associated with hallucinations. In clinical trials, hallucinations developed in approximately 4.0% of patients treated with 200 mg Comtan or placebo. Hallucinations led to drug discontinuation and premature withdrawal from clinical trials in 0.8% and 0% of patients treated with 200 mg Comtan and placebo, respectively. Hallucinations led to hospitalization in 1.0% and 0.3% of patients in the 200 mg Comtan and placebo groups, respectively.

Comtan may potentiate the dopaminergic side effects of levodopa and may cause and/or exacerbate preexisting dyskinesia. Although decreasing the dose of levodopa may ameliorate this side effect, many patients in controlled trials continued to experience frequent dyskinesias despite a reduction in their dose of levodopa. The rates of withdrawal for dyskinesia were 1.5% and 0.8% for 200 mg Comtan and placebo, respectively.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  


Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium



Clopidogrel Bisulfate



Atomoxetine Hcl



Desmopressin Monoacetate


Divalproex Sodium


Dobutamine Hcl

Bupropion Hcl



Dothiepin Hcl






Escitalopram HBr





Cefuroxime Axetil



Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.